Related content

Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab

By Chamberlain Marc   Johnston Sandra  

Journal of Neuro-Oncology, Vol. 102, Iss. 3, 2011-05 ,pp. : 427-432

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

By Reardon David   Desjardins Annick   Peters Katherine   Gururangan Sridharan   Sampson John   Rich Jeremy   McLendon Roger   Herndon James   Marcello Jennifer   Threatt Stevie   Friedman Allan   Vredenburgh James   Friedman Henry  

Journal of Neuro-Oncology, Vol. 103, Iss. 2, 2011-06 ,pp. : 371-379

Springer Publishing Company

Access to resources Recommend Favorite

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

By Zuniga Richard   Torcuator Roy   Jain Rajan   Anderson John   Doyle Thomas   Schultz Lonni   Mikkelsen Tom  

Journal of Neuro-Oncology, Vol. 99, Iss. 2, 2010-09 ,pp. : 237-242

Springer Publishing Company

Access to resources Recommend Favorite

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

By Møller Søren   Grunnet Kirsten   Hansen Steinbjørn   Schultz Henrik   Holmberg Mats   Sorensen Morten   Poulsen Hans S.   Lassen Ulrik  

Acta Oncologica, Vol. 51, Iss. 6, 2012-07 ,pp. : 797-804

Informa Healthcare

Access to resources Recommend Favorite

Validation of Nomogram-based Prediction of Survival Probability after Salvage Re-irradiation of Head and Neck Cancer

By Shikama Naoto   Kumazaki Yu   Tsukamoto Nobuhiro   Ebara Takeshi   Makino Soichi   Abe Takanori   Nakahira Mitsuhiko   Sugasawa Masashi   Kato Shingo  

Japanese Journal of Clinical Oncology, Vol. 43, Iss. 2, 2013-02 ,pp. : 154-160

Oxford University Press

Access to resources Recommend Favorite